You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-PD1/PDL1

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

Not yet recruiting
  • Hepatocellular Carcinoma Non-resectable
  • transarterial therapies
  • (no location specified)
Nov 27, 2022

Multiple Myeloma Trial (Bone marow biopsy and aspiration, biochemical and heamatological tests)

Not yet recruiting
  • Multiple Myeloma
  • Bone marow biopsy and aspiration
  • biochemical and heamatological tests
  • (no location specified)
Aug 9, 2023

Metastatic Non Small Cell Lung Cancer Trial in Singapore (Nivolumab, ADG106)

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Singapore, Singapore
  • +1 more
Mar 10, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Urothelial Carcinoma Trial in Ann Arbor (Pembrolizumab, SBRT)

Terminated
Has Results
  • Urothelial Carcinoma
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Dec 13, 2021

Generation ofArtificial Intelligence Algorithm Based on Analysis

Not yet recruiting
  • Metastatic Melanoma
  • Photo
  • (no location specified)
May 3, 2023

Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy Trial in Leiden (Nivolumab & Tumor Infiltrating Lymphocytes

Recruiting
  • Toxicity, Drug
  • +2 more
  • Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
  • Leiden, Netherlands
    Leiden University Medical Center
Aug 16, 2022

Lung Cancer, Liver Cancer, Colorectal Cancer Trial in Guangzhou (ipilimumab +pembrolizumab +durvalumab)

Recruiting
  • Lung Cancer
  • +10 more
  • ipilimumab +pembrolizumab +durvalumab
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Jan 10, 2022

Esophagus Cancer, Bladder Cancer, Liver Cancer Trial (Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal

Not yet recruiting
  • Esophagus Cancer
  • +4 more
  • Intravenous injection of P-IL-2
  • P-IL-2 plus Anti-PD-1 Monoclonal Antibody
  • (no location specified)
Apr 24, 2023

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer Trial in Lyon, Toulouse (Pexidartinib, Durvalumab)

Completed
  • Colorectal Cancer
  • +3 more
  • Lyon, France
  • +1 more
Sep 2, 2021

Metastatic Melanoma Trial in Irvine, Newport Beach (AV-MEL-1)

Recruiting
  • Metastatic Melanoma
  • Irvine, California
  • +1 more
Dec 14, 2021

Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Helsinki (TILT-123, Avelumab)

Recruiting
  • Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Helsinki, Finland
    Docrates Cancer Center
Jul 12, 2022

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Recruiting
  • Graft Rejection
  • +3 more
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
Jun 21, 2023

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

Castrate-Resistant Prostate Cancer Trial in Hangzhou (PD1-PSMA-CART cells)

Recruiting
  • Castrate-Resistant Prostate Cancer
  • PD1-PSMA-CART cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
Feb 26, 2022

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
Sep 2, 2023

Head Neck Cancer Trial in Madison (NKTR-214, anti-PD-1 therapy, Palliative Radiation)

Active, not recruiting
  • Head and Neck Cancer
  • Madison, Wisconsin
    University of Wisconsin
May 9, 2022

NSCLC Trial (Dupilumab, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Dupilumab
  • Cemiplimab
  • (no location specified)
Oct 12, 2023

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023